There are currently 842 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059
Recruiting
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/05/2025
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Recruiting
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Research Site, Jacksonville, Florida
Conditions: Relapsed/ Refractory Multiple Myeloma
Register for Updates
A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients
NCT05803551
Recruiting
The purpose of this research is to study the effects of intravenous ketamine infusions for the treatment of patients with depressive symptoms in intensive care unit (ICU).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/05/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Depression
Register for Updates
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616
Recruiting
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Breast Cancer
Register for Updates
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin a... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/05/2025
Locations: Research Site, Jacksonville, Florida
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/05/2025
Locations: Research Site, Jacksonville, Florida
Conditions: Acute Coronary Syndrome
Register for Updates
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717
Recruiting
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: GSK Investigational Site, Jacksonville, Florida
Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Register for Updates
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509
Recruiting
This study is open to adults who participated in a previous clinical study with brigimadlin. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants are grouped in cohorts depending on their treatment in the previous study: * Cohort 1a got brigimadlin and continues treatment with brigimadlin * Cohort 1b got brigimadlin for 4 or less tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Mayo Clinic Cancer Center, Jacksonville, Florida
Conditions: Solid Tumours
Register for Updates
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125
Recruiting
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/05/2025
Locations: Nemours Children's Health, Jacksonville, Florida
Conditions: Dravet Syndrome
Register for Updates
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
NCT06975722
Recruiting
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Green Leaf Clinical Trials - Site Number: 8400024, Jacksonville, Florida
Conditions: Ulcerative Colitis
Register for Updates
Abbott Medical - VERITAS Study
NCT06707688
Recruiting
The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Baptist Medical Center, Jacksonville, Florida
Conditions: Atrial Fibrillation (AF), Stoke
Register for Updates
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785
Recruiting
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Research Site, Jacksonville, Florida
Conditions: Hepatocellular Carcinoma
Register for Updates